Regeneron Pharmaceuticals, Inc.

Kishor Devalaraja-Narashimha

Karolina Meagher

Lori C Morton

Jeffrey D Lee

Yifan Luo

Sarah Casanova

Cong Huang

The present invention relates to combinations of anti-C5 antibodies and antigen-binding fragments which have been determined to exhibit superior activity relative to that of a single anti-C5 antibody or fragment. The combinations include anti-C5 antibodies and antigen-binding fragments which do not compete with one another from C5 binding. Bispecific antibodies comprising antigen-binding domains which do not compete and/or bind the same epitope on C5 are also provided. Compositions and therapeutic methods relating to such anti-C5 combinations and bispecific antibodies are provided herein.

Anti-C5 antibody combinations and uses thereof

Provided herein, inter alia, are non-human animals comprising nucleic acid sequences encoding a C3 protein that comprises a human sequence as well as transgenic non-human animals comprising a C3 gene that is human in whole or in part as well as methods for using the same to screen for candidate therapeutic molecules to treat complement-related nephropathies. Also provided herein are methods for improving kidney function in an individual diagnosed with or thought to have a complement-related nephropathy.

Humanized model of kidney and liver disorders

Growing community of inventors

Yorktown Heights, NY, United States of America

Kishor Devalaraja-Narashimha